SMC Q1 FY27 profit attributable to owners of parent more than doubled to JPY 67.86 billion year-on-year; net sales rise 35.4% to JPY 270.99 billion
Reuters2026/08/07 05:05- SMC posted Q1 net sales of JPY 270.99 billion, up 35.4% year over year under Japanese GAAP.
- Operating profit climbed to JPY 73.99 billion, up 66.4% year over year.
- Profit attributable to owners of parent more than doubled to JPY 67.86 billion, up 95.9% year over year.
- Ordinary profit rose to JPY 91.79 billion, up 86.9% year over year, due to foreign exchange gains and securities-sale gains.
- Kept its FY ending March 31, 2027 forecast unchanged, targeting net sales of JPY 1 trillion, operating profit of JPY 219 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Moderna melanoma vaccine data gains recognition; fifth institution upgrades rating
Moderna has recently received consecutive rating upgrades from five institutions due to positive clinical data from its melanoma mRNA cancer vaccine. Argus analyst Hellweg upgraded the company's rating from "hold" to "buy," noting that the stock price is currently trading at over a 70% discount from its historical peak and believing that "the tide is turning." He emphasized that the stock price increase driven by existing data is just the beginning, and that continued positive confirmatory data will provide stronger upward momentum.
South Korean Won: Higher rates and chip boom support gains – ING
AJB Investment Fund II reports buying Jewett-Cameron common shares worth $7,350.20
Morgan Stanley trims ADTRAN stake to 6.77% from 6.8%
Crypto prices
More
